Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EWING2008 Study in Ewing Sarcoma
NCT00987636Phase 3Completed
- Sponsor
- Universitätsklinikum Münster
- Start
- Oct 2009
- Primary completion
- Mar 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid, busulfan and treosulfan in Ewing sarcoma (6 arms), sponsored by Universitätsklinikum Münster. Primary endpoint: Event Free Survival at 9.5 years. Started Oct 2009; status: completed.
02
Drugs
zoledronic acidbusulfantreosulfan
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT00987636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00987636.